UC Health Diabetes Health Update
Live Virtual Learning
December 15, 2021
This course will review the latest guidelines, evidence, and interventions to manage patients with diabetes. The discussion will focus on describing the benefits, side effects, and contraindications of GLP-1 Receptor Agonists and SGLT-2 Inhibitors.
Registration for this course is free to all UC physicians whose practice includes care for patients with diabetes.
- Complimentary for all UC physicians whose practice includes care for patients with diabetes
To enroll, click here.
*Note: To ensure course material is received before the course begins, early registration is advised. Online registration will close at 11:59 PM on Monday, December 13th.
Enrollment on the day of the course: To register the day of the conference, or for any virtual conference related questions, please reach out to our CME registration staff at (310) 794-2620.
Matthew J. Freeby, MD is an Assistant Clinical Professor of Medicine, Director of the Gonda Diabetes Center and the Associate Director of Diabetes Clinical Programs at the David Geffen UCLA School of Medicine.
Upon completion of this program, participants should be able to:
- Describe benefits, including A1C reduction, weight changes, and cardiorenal outcomes with GLP-1 Receptor Agonists and SGLT-2 Inhibitors
- Discuss side effect profiles of GLP-1 Receptor Agonists and SGLT-2 Inhibitors
- Review contraindications to GLP-1 Receptor Agonists and SGLT-2 Inhibitors
The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The California State Board of Registered Nursing accepts courses approved by the AMA for category 1 credit as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.
The FDA has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is “truly independent” and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program’s participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manage all identified potential conflicts of interest prior to the program. We, at UCLA, fully endorse the letter and spirit of these concepts.